July 31, 2017 09:49 AM EDT

AstraZeneca bags a ‘breakthrough’ for bruised checkpoint drug Imfinzi; Inotek CSO takes the helm at Flex

Shehla Shakoor

Managing Director

→ Just days after a damaging failure for duvalumab (Imfinzi) in a combination approach to lung cancer, the FDA has designated AstraZeneca’s checkpoint inhibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca bags a ‘breakthrough’ for bruised checkpoint drug Imfinzi; Inotek CSO takes the helm at Flex

Shehla Shakoor

Managing Director

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Sofinnova outlines $550M fund after IPOs and M&A deals

As­traZeneca bags a ‘break­through’ for bruised check­point drug Imfinzi; In­otek CSO takes the helm at Flex

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

AstraZeneca bags a ‘breakthrough’ for bruised checkpoint drug Imfinzi; Inotek CSO takes the helm at Flex

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Sofinnova outlines $550M fund after IPOs and M&A deals